{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:53:23Z","timestamp":1787770403503,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2016-10424"],"award-info":[{"award-number":["2016-10424"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.esmoop.2024.102248","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T12:44:56Z","timestamp":1707741896000},"page":"102248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9010-4919","authenticated-orcid":false,"given":"Y.M.","family":"Geurts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-4298","authenticated-orcid":false,"given":"S.I.M.","family":"Neppelenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-6590","authenticated-orcid":false,"given":"B.M.P.","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.M.","family":"Janus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3257-3634","authenticated-orcid":false,"given":"A.D.G.","family":"Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"van Spronsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-0405","authenticated-orcid":false,"given":"J.M.","family":"Roesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2112-4443","authenticated-orcid":false,"given":"K.M.S.","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Koene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-4939","authenticated-orcid":false,"given":"M.R.","family":"Nijziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.C.","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-5794","authenticated-orcid":false,"given":"E.","family":"de Jongh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.C.J.","family":"te Boome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-706X","authenticated-orcid":false,"given":"R.S.","family":"van Rijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.D.P.","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7505-0780","authenticated-orcid":false,"given":"H.P.J.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.F.M.","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-3407","authenticated-orcid":false,"given":"Y.M.","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4151-2865","authenticated-orcid":false,"given":"C.","family":"So-Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.P.","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"de Weijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.E.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schaapveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2024.102248_bib1","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2024.102248_bib2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102248_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102248_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102248_bib5","series-title":"IKNL. Het diffuus grootcellig B-cellymfoom in Nederland, 2014-2016","year":"2019"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102248_bib6","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1182\/blood-2007-08-106021","article-title":"Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"111","author":"Bluhm","year":"2008","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.esmoop.2024.102248_bib7","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102248_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","article-title":"Risk of multiple primary malignancies following treatment of Hodgkin lymphoma","volume":"124","author":"van Eggermond","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102248_bib9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.102248_bib10","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1001\/jama.2011.747","article-title":"Long-term risks of subsequent primary neoplasms among survivors of childhood cancer","volume":"305","author":"Reulen","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102248_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102248_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2019.100502","article-title":"Second primary malignancy in diffuse large B-cell lymphoma patients: a SEER database analysis","volume":"44","author":"Jiang","year":"2020","journal-title":"Curr Probl Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2024.102248_bib13","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1080\/10428194.2020.1811862","article-title":"Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma","volume":"61","author":"Chinen","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102248_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.14638","article-title":"Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era","volume":"178","author":"Tao","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102248_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/cncr.29841","article-title":"Therapeutic radiation and the potential risk of second malignancies","volume":"122","author":"Kamran","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102248_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2012.09.001","article-title":"Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship","volume":"86","author":"Berrington de Gonzalez","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102248_bib17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3109\/10428194.2012.743657","article-title":"Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102248_bib18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.esmoop.2024.102248_bib19","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","article-title":"Risk of leukemia after chemotherapy and radiation treatment for breast cancer","volume":"326","author":"Curtis","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102248_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.2006.05.9048","article-title":"Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer","volume":"25","author":"Le Deley","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.102248_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2015.65.0465","article-title":"Anthracyclines and alkylating agents: new risk factors for breast cancer in childhood cancer survivors?","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2024.102248_bib22","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1111\/febs.15583","article-title":"New insights into the activities and toxicities of the old anticancer drug doxorubicin","volume":"288","author":"van der Zanden","year":"2021","journal-title":"FEBS J"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102248_bib23","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102248_bib24","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1080\/10428194.2020.1779257","article-title":"Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen","volume":"61","author":"Neeman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102248_bib26","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/bjh.15936","article-title":"Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma","volume":"186","author":"Nijdam","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2024.102248_bib27","first-page":"A9269","article-title":"[The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment]","volume":"159","author":"Dekker","year":"2015","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2024.102248_bib28","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102248_bib29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2021013998","article-title":"Limited-stage diffuse large B-cell lymphoma","volume":"139","author":"Hawkes","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102248_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102248_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102248_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.102248_bib33","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102248_bib34","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102248_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"issue":"82","key":"10.1016\/j.esmoop.2024.102248_bib36","first-page":"1","article-title":"Statistical methods in cancer research. Volume II--The design and analysis of cohort studies","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102248_bib37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"23","key":"10.1016\/j.esmoop.2024.102248_bib38","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/jnci\/85.23.1932","article-title":"Second cancers among long-term survivors of non-Hodgkin\u2019s lymphoma","volume":"85","author":"Travis","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102248_bib39","article-title":"Second primary malignancies in diffuse large B-cell lymphoma survivors with 40 years of follow up: influence of chemotherapy and radiation therapy","volume":"7","author":"Rock","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102248_bib40","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/annonc\/mdq697","article-title":"Risk for second malignancies in non-Hodgkin\u2019s lymphoma survivors: a meta-analysis","volume":"22","author":"Pirani","year":"2011","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.102248_bib41","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102248_bib42","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: the relation to age at treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2024.102248_bib43","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2016.71.6902","article-title":"Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER Study Cohort: role of chemotherapy","volume":"35","author":"Teepen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102248_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-021-00574-5","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018","volume":"11","author":"Dinnessen","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102248_bib45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102248_bib46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2024.102248_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJM198804213181604","article-title":"Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin\u2019s lymphoma","volume":"318","author":"Pedersen-Bjergaard","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2024.102248_bib48","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","article-title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","volume":"29","author":"Lyman","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102248_bib49","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-014-2099-8","article-title":"Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry","volume":"93","author":"Oerlemans","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102248_bib50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10428194.2020.1842394","article-title":"A\u00a0population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands","volume":"62","author":"Issa","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102248_bib51","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5993\/AJHB.27.3.6","article-title":"Do adults change their lifestyle behaviors after a cancer diagnosis?","volume":"27","author":"Blanchard","year":"2003","journal-title":"Am J Health Behav"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102248_bib52","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/pbc.20421","article-title":"Health-risk behaviours among adolescent survivors of childhood cancer","volume":"45","author":"Bauld","year":"2005","journal-title":"Pediatr Blood Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924000164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924000164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:49:15Z","timestamp":1778834955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2059702924000164"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102248","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102248"}}